Document and Entity Information
|
6 Months Ended | |
---|---|---|
Jun. 30, 2013
|
Aug. 30, 2013
|
|
Document and Entity Information | ||
Entity Registrant Name | Onconova Therapeutics, Inc. | |
Entity Central Index Key | 0001130598 | |
Document Type | 10-Q | |
Document Period End Date | Jun. 30, 2013 | |
Amendment Flag | false | |
Current Fiscal Year End Date | --12-31 | |
Entity Current Reporting Status | No | |
Entity Filer Category | Non-accelerated Filer | |
Entity Common Stock, Shares Outstanding | 21,403,655 | |
Document Fiscal Year Focus | 2013 | |
Document Fiscal Period Focus | Q2 |
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
X | ||||||||||
- Details
|
X | ||||||||||
- Definition
Total of the carrying values, as of the balance sheet date, of obligations incurred through that date and payable for obligations related to accrued expenses and other costs not separately disclosed in the balance sheet. It is used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). No definition available.
|
X | ||||||||||
- Definition
This element represents a security that gives the holder the right to purchase shares of common stock, in accordance with the terms of the instrument, usually upon payment of a specified amount, due within one year or within the normal operating cycle if longer. No definition available.
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
X | ||||||||||
- Details
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
X | ||||||||||
- Details
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
X | ||||||||||
- Details
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
Condensed Consolidated Balance Sheets (Parenthetical) (USD $)
|
Jun. 30, 2013
|
---|---|
Condensed Consolidated Balance Sheets | |
Redeemable convertible preferred stock, par value per share (in dollars per share) | $ 0.01 |
Redeemable convertible preferred stock, shares authorized | 18,548,253 |
Redeemable convertible preferred stock, shares issued | 16,912,199 |
Redeemable convertible preferred stock, shares outstanding | 16,912,199 |
Redeemable convertible preferred stock, liquidation preference (in dollars) | $ 205,760,000 |
Common stock, par value (in dollars per share) | $ 0.01 |
Common stock, shares authorized | 30,145,155 |
Common stock, shares issued | 2,609,484 |
Common stock, shares outstanding | 2,609,484 |
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
X | ||||||||||
- Details
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
Condensed Consolidated Statements of Operations (USD $)
|
3 Months Ended | 6 Months Ended | ||
---|---|---|---|---|
Jun. 30, 2013
|
Jun. 30, 2012
|
Jun. 30, 2013
|
Jun. 30, 2012
|
|
Condensed Consolidated Statements of Operations | ||||
Revenue | $ 591,000 | $ 220,000 | $ 1,707,000 | $ 418,000 |
Operating expenses: | ||||
General and administrative | 3,117,000 | 1,627,000 | 6,463,000 | 4,087,000 |
Research and development | 10,047,000 | 6,776,000 | 22,803,000 | 15,224,000 |
Total operating expenses | 13,164,000 | 8,403,000 | 29,266,000 | 19,311,000 |
Loss from operations | (12,573,000) | (8,183,000) | (27,559,000) | (18,893,000) |
Change in fair value of warrant liability | (2,000) | 999,000 | 12,000 | 390,000 |
Interest expense | (2,000) | (230,000) | (2,000) | (251,000) |
Other income (expense), net | 15,000 | (2,000) | 142,000 | 539,000 |
Net loss before income taxes | (12,562,000) | (7,416,000) | (27,407,000) | (18,215,000) |
Net loss | (12,562,000) | (7,416,000) | (27,407,000) | (18,215,000) |
Accretion of redeemable convertible preferred stock | (1,032,000) | (927,000) | (2,051,000) | (2,158,000) |
Net loss applicable to common stockholders | $ (13,594,000) | $ (8,343,000) | $ (29,458,000) | $ (20,373,000) |
Net loss per share of common stock, basic and diluted (in dollars per share) | $ (5.21) | $ (3.84) | $ (11.29) | $ (9.37) |
Basic and diluted weighted average shares outstanding (in shares) | 2,609,495 | 2,173,549 | 2,608,450 | 2,173,549 |
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
X | ||||||||||
- Details
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
X | ||||||||||
- Details
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
Condensed Consolidated Statements of Comprehensive Loss (USD $)
|
3 Months Ended | 6 Months Ended | ||
---|---|---|---|---|
Jun. 30, 2013
|
Jun. 30, 2012
|
Jun. 30, 2013
|
Jun. 30, 2012
|
|
Condensed Consolidated Statements of Comprehensive Loss | ||||
Net loss | $ (12,562,000) | $ (7,416,000) | $ (27,407,000) | $ (18,215,000) |
Other comprehensive (loss) income, before tax: | ||||
Foreign currency translation adjustments, net | (2,000) | 5,000 | ||
Other comprehensive (loss) income, net of tax | (2,000) | 5,000 | ||
Comprehensive loss | $ (12,564,000) | $ (7,416,000) | $ (27,402,000) | $ (18,215,000) |
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
X | ||||||||||
- Details
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
X | ||||||||||
- Details
|
Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders' Deficit (USD $)
|
Total
|
Redeemable Convertible Preferred Stock
|
Common Stock
|
Additional Paid in Capital
|
Accumulated deficit
|
Accumulated other comprehensive income (loss)
|
---|---|---|---|---|---|---|
Balance at Dec. 31, 2011 | $ (138,419,000) | $ 119,997,000 | $ 22,000 | $ (138,441,000) | ||
Balance (in shares) at Dec. 31, 2011 | 11,227,169 | 2,167,928 | ||||
Increase (Decrease) in Stockholders' Equity | ||||||
Net loss | (18,215,000) | (18,215,000) | ||||
Exercise of stock options | 9,000 | 9,000 | ||||
Exercise of stock options (in shares) | 5,700 | |||||
Settlement of stock option liabilities | 34,000 | 34,000 | ||||
Issuance of preferred stock upon exercise of warrants | 2,802,000 | |||||
Issuance of preferred stock upon exercise of warrants (in shares) | 221,399 | |||||
Accretion of preferred stock to redemption value | (2,158,000) | 2,158,000 | (43,000) | (2,115,000) | ||
Balance at Jun. 30, 2012 | (158,749,000) | 124,957,000 | 22,000 | (158,771,000) | ||
Balance (in shares) at Jun. 30, 2012 | 11,448,568 | 2,173,628 | ||||
Balance at Dec. 31, 2012 | (158,306,000) | 201,315,000 | 26,000 | 10,021,000 | (168,353,000) | |
Balance (in shares) at Dec. 31, 2012 | 2,606,484 | 16,912,199 | 2,606,484 | |||
Increase (Decrease) in Stockholders' Equity | ||||||
Net loss | (27,407,000) | (27,407,000) | ||||
Other comprehensive income | 5,000 | 5,000 | ||||
Exercise of stock options | 44,000 | 44,000 | ||||
Exercise of stock options (in shares) | 3,000 | |||||
Stock based compensation | 291,000 | 291,000 | ||||
Accretion of preferred stock to redemption value | (2,051,000) | 2,051,000 | (2,051,000) | |||
Modification of stock option awards | 14,482,000 | 14,482,000 | ||||
Balance at Jun. 30, 2013 | $ (172,942,000) | $ 203,366,000 | $ 26,000 | $ 22,787,000 | $ (195,760,000) | $ 5,000 |
Balance (in shares) at Jun. 30, 2013 | 2,609,484 | 16,912,199 | 2,609,484 |
X | ||||||||||
- Definition
Amount of increase in additional paid in capital (APIC) resulting from settlement of option liability. No definition available.
|
X | ||||||||||
- Definition
Amount of increase in additional paid in capital (APIC) resulting from modification of stock option awards. No definition available.
|
X | ||||||||||
- Definition
Represents the number of shares of temporary stock issued during the period upon exercise of warrants. No definition available.
|
X | ||||||||||
- Definition
Represents the value of temporary stock issued during the period upon exercise of warrants. No definition available.
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
X | ||||||||||
- Details
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
X | ||||||||||
- Definition
The increase (decrease) during the reporting period in grants receivable. No definition available.
|
X | ||||||||||
- Details
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
X | ||||||||||
- Details
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
X | ||||||||||
- Details
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
X | ||||||||||
- Details
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
X | ||||||||||
- Details
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
Nature of Business
|
6 Months Ended |
---|---|
Jun. 30, 2013
|
|
Nature of Business | |
Nature of Business | 1. Nature of Business
The Company
Onconova Therapeutics, Inc. (the “Company”) was incorporated in the State of Delaware on December 22, 1998 and commenced operations on January 1, 1999. The Company’s headquarters are located in Newtown, Pennsylvania. The Company is a clinical-stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer. Using its proprietary chemistry platform, the Company has created an extensive library of targeted anti-cancer agents designed to work against specific cellular pathways that are important to cancer cells. The Company believes that the drug candidates in its pipeline have the potential to be efficacious in a wide variety of cancers without causing harm to normal cells. The Company has three clinical-stage product candidates and six preclinical programs. To accelerate and broaden the development of rigosertib, the Company’s most advanced product candidate, the Company entered into a collaboration and license agreement with Baxter Healthcare SA (“Baxter”), a subsidiary of Baxter International Inc., in 2012 to commercialize rigosertib in Europe. In 2011, the Company entered into a collaboration and license agreement with SymBio Pharmaceuticals Limited (“SymBio”) to commercialize rigosertib in Japan and Korea. The Company has retained development and commercialization rights to rigosertib in the rest of the world, including the United States. During 2012, Onconova Europe GmbH was established as a wholly owned subsidiary of the Company for the purpose of further developing business in Europe.
Liquidity
The Company has incurred recurring operating losses since inception. For the six months ended June 30, 2013, the Company incurred a net loss of $27,407,000 and as of June 30, 2013, the Company had generated an accumulated deficit of $195,760,000. The Company anticipates operating losses to continue for the foreseeable future due to, among other things, costs related to research funding, development of its product candidates and its preclinical programs, strategic alliances and the development of its administrative organization.
The Company has raised significant capital through the issuance of its redeemable convertible preferred stock, par value $0.01 per share, in ten series denominated as Series A through Series J (“Series A Preferred Stock” through “Series J Preferred Stock,” respectively, and collectively the “Preferred Stock”). See Note 6.
On July 30, 2013, the Company completed its initial public offering (the “IPO”) of 5,941,667 shares of the Company’s common stock, par value $0.01 per share (“Common Stock”), at a price of $15.00 per share, including 775,000 shares of Common Stock issued upon the exercise in full by the underwriters of their option to purchase additional shares at the same price to cover over-allotments. The Company received net proceeds of $79,600,000 from the sale, net of underwriting discounts and commissions and other estimated offering expenses. Immediately prior to the consummation of the IPO, all outstanding shares of Preferred Stock automatically converted into shares of Common Stock at the applicable conversion ratio then in effect. As a result of the conversion, as of July 30, 2013, the Company had no shares of Preferred Stock outstanding.
The accompanying condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The Company’s ability to continue as a going concern is dependent on its ability to raise additional capital to fund its research and development and commercial programs and meet its obligations. Management intends to fund future operations through additional equity offerings, licensing revenue, grants, government contracts and, if any of the Company’s product candidates receive marketing approval, future sales of its products. There can be no assurance, however, that the Company will be successful in obtaining financing at the level needed to sustain operations or on terms acceptable to the Company, or that the Company will obtain approvals necessary to market its products or achieve profitability or sustainable, positive cash flow.
The Company faces many risks associated with companies in the early stages. It also faces risks inherent in its business and its industry generally. These risks include, among others, the following:
· the Company’s success is primarily dependent on the regulatory approval and commercialization of rigosertib;
· the Company is subject to regulatory approval processes that are lengthy, time consuming, expensive and unpredictable. The Company may not obtain approval on a timely basis or at all for any of its product candidates from the U.S. Food and Drug Administration or foreign regulatory authorities;
· the Company has no significant source of product revenue, may never become profitable and may incur substantial and increasing net losses for the foreseeable future as it continues to develop and seek regulatory approvals for, and potentially begins to commercialize, its product candidates;
· the Company may need to obtain additional funding to continue operations;
· it is difficult and costly to protect the Company’s intellectual property rights;
· the Company may be unable to recruit or retain key employees, including its senior management team; and
· the Company depends on the performance of third parties, including contract research organizations and third-party manufacturers. |
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
X | ||||||||||
- Details
|
Summary of Significant Accounting Policies
|
6 Months Ended |
---|---|
Jun. 30, 2013
|
|
Summary of Significant Accounting Policies | |
Summary of Significant Accounting Policies | 2. Summary of Significant Accounting Policies
Basis of Presentation
The condensed consolidated financial statements are prepared in conformity with accounting principles generally accepted in the United States (“GAAP”) for interim financial information. Certain information and footnotes normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to the rules and regulations of the Securities and Exchange Commission. The financial statements include the consolidated accounts of the Company and its wholly-owned subsidiary, Onconova Europe GmbH. All significant intercompany transactions have been eliminated.
Unaudited Interim Financial Information
The accompanying condensed consolidated balance sheet as of June 30, 2013, the condensed consolidated statements of operations and comprehensive loss for the three and six months ended June 30, 2013 and 2012, the condensed consolidated statements of redeemable convertible preferred stock and stockholders’ deficit and the condensed consolidated statements of cash flows for the six months ended June 30, 2013 and 2012 are unaudited. The interim unaudited condensed consolidated financial statements have been prepared on the same basis as the annual audited consolidated financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary for the fair statement of the Company’s financial position as of June 30, 2013 and the results of its operations, its comprehensive loss and its cash flows for the six months ended June 30, 2013 and 2012. The financial data and other information disclosed in these notes related to the six months ended June 30, 2013 and 2012 are unaudited. The results for the six months ended June 30, 2013 are not necessarily indicative of results to be expected for the year ending December 31, 2013, any other interim periods, or any future year or period. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the notes thereto for the year ended December 31, 2012 included in the Company’s final prospectus filed on July 25, 2013 with the Securities and Exchange Commission (the “SEC”) pursuant to Rule 424(b)(4) of the Securities Act of 1933, as amended (the “Securities Act”).
Segment Information
Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business in one segment, which is the identification and development of oncology therapeutics.
Significant Accounting Policies
The Company’s significant accounting policies are disclosed in the audited consolidated financial statements for the year ended December 31, 2012 included in the Company’s final prospectus filed on July 25, 2013 with the SEC pursuant to Rule 424(b)(4) of the Securities Act. Since the date of such financial statements, there have been no changes to the Company’s significant accounting policies.
Foreign Currency Translation
The reporting currency of the Company and its U.S. subsidiary is the U.S. dollar. The functional currency of the Company’s non-U.S. subsidiary is the local currency. Assets and liabilities of the foreign subsidiary are translated into U.S. dollars based on exchange rates at the end of the period. Revenues and expenses are translated at average exchange rates during the reporting period. Gains and losses arising from the translation of assets and liabilities are included as a component of accumulated other comprehensive income. Gains and losses resulting from foreign currency transactions are reflected within the Company’s results of operations. The Company has not utilized any foreign currency hedging strategies to mitigate the effect of its foreign currency exposure.
Deferred Initial Public Offering Costs
Deferred IPO costs as of June 30, 2013, consisting of legal, accounting, printing and filing fees incurred in the preparation of the Company’s Registration Statement on Form S-1 were capitalized. The deferred costs are included in prepaid expenses and other current assets on the consolidated balance sheets. See Note 5. The deferred offering costs were offset against the IPO proceeds upon the completion of the offering in July 2013.
Recent Accounting Pronouncements
In February 2013, the Financial Accounting Standards Board (the “FASB”) amended its guidance to require an entity to present the effect of certain significant reclassifications out of accumulated other comprehensive income on the respective line items in net income. The new accounting guidance does not change the items that must be reported in other comprehensive income or when an item of other comprehensive income must be reclassified to net income. The guidance is effective prospectively for fiscal years beginning after December 15, 2012. The Company adopted these new provisions for the quarter beginning January 1, 2013. As the guidance requires additional presentation only, there was no impact to the Company’s consolidated financial position, results of operations or cash flows.
In July 2013, the FASB issued guidance clarifying that an unrecognized tax benefit, or a portion of an unrecognized tax benefit, should be presented in the financial statements as a reduction to a deferred tax asset for a net operating loss carryforward, a similar tax loss, or a tax credit carryforward if such settlement is required or expected in the event the uncertain tax benefit is disallowed. In situations where a net operating loss carryforward, a similar tax loss, or a tax credit carryforward is not available at the reporting date under the tax law of the applicable jurisdiction or the tax law of the jurisdiction does not require, and the entity does not intend to use, the deferred tax asset for such purpose, the unrecognized tax benefit should be presented in the financial statements as a liability and should not be netted with the deferred tax asset. The guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2013. Early adoption is permitted. The amendments should be applied prospectively to all unrecognized tax benefits that exist at the effective date. Retrospective application is permitted. The Company is currently evaluating the impact that adoption will have on the determination or reporting of its financial results. |
X | ||||||||||
- Details
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
Fair Value Measurements
|
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2013
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair Value Measurements | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair Value Measurements | 3. Fair Value Measurements
The Company applies various valuation approaches in determining the fair value of its financial assets and liabilities within a hierarchy that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the inputs that market participants would use in pricing the asset or liability and are developed based on the best information available under the circumstances. The fair value hierarchy is broken down into three levels based on the source of inputs as follows:
Level 1—Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access.
Level 2—Valuations based on quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active and models for which all significant inputs are observable, either directly or indirectly.
Level 3—Valuations based on inputs that are unobservable and significant to the overall fair value measurement.
The availability of observable inputs can vary among the various types of financial assets and liabilities. To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, for financial statement disclosure purposes, the level in the fair value hierarchy within which the fair value measurement is classified is based on the lowest level input that is significant to the overall fair value measurement.
The Company had no assets or liabilities classified as Level 1 or Level 2. The Series G Preferred Stock warrants (see Note 6) are classified as Level 3. The fair values of these instruments are determined using models based on market observable inputs and management judgment. There were no material re-measurements of fair value during the six months ended June 30, 2013 and the year ended December 31, 2012 with respect to financial assets and liabilities, other than those assets and liabilities that are measured at fair value on a recurring basis.
The Company has classified the Series G Preferred Stock warrants as a liability and has re-measured the liability to estimated fair value at June 30, 2013 and December 31, 2012, using the Black-Scholes option pricing model with the following assumptions: contractual life according to the remaining terms of the warrants, no dividend yield, weighted average risk-free interest rates of 0.33% and 0.31% at June 30, 2013 and December 31, 2012, respectively, and weighted average volatility of 72.07% and 64.87% at June 30, 2013 and December 31, 2012, respectively. The volatility was based on average historical share price trading data for a group of 11 comparable companies.
The following fair value hierarchy table presents information about the Company’s financial assets and liabilities measured at fair value on a recurring basis as of June 30, 2013 and December 31, 2012:
The following table presents a reconciliation of the Company’s liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) for the six months ended June 30, 2013:
There were no transfers between Level 1 and Level 2 in any of the periods reported. |
X | ||||||||||
- Details
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
Net Loss Per Share of Common Stock
|
6 Months Ended | ||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2013
|
|||||||||||||||||||||||||||||||||||||
Net Loss Per Share of Common Stock | |||||||||||||||||||||||||||||||||||||
Net Loss Per Share of Common Stock | 4. Net Loss Per Share of Common Stock
The following potentially dilutive securities outstanding at June 30, 2013 and 2012 have been excluded from the computation of diluted weighted average shares outstanding, as they would be antidilutive:
|
X | ||||||||||
- Details
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
Balance Sheet Detail
|
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2013
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Balance Sheet Detail | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Balance Sheet Detail | 5. Balance Sheet Detail
Prepaid expenses and other current assets:
Property and equipment:
Accrued expenses and other current liabilities:
|
X | ||||||||||
- Details
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
Preferred Stock and Stockholders' Deficit
|
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2013
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Preferred Stock and Stockholders' Deficit | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Preferred Stock and Stockholders' Deficit | 6. Preferred Stock and Stockholders’ Deficit
Capitalization
The following is the composition of share capital as of the dates indicated:
In preparation for the IPO, the Company’s board of directors and stockholders approved a one-for-1.333 reverse stock split of the Company’s Common Stock. The reverse stock split became effective on July 17, 2013. All Common Stock share and per share amounts in the condensed consolidated financial statements and notes thereto have been retroactively adjusted for all periods presented to give effect to this reverse stock split, including reclassifying an amount equal to the reduction in par value of common stock to additional paid-in capital. The reverse stock split did not result in a retroactive adjustment of share amounts for the Preferred Stock.
In July 2012, the Company issued 2,433,328 shares of Series I Preferred Stock in exchange for the conversion of the convertible promissory notes and accrued interest in the amount of $26,444,000 and $323,000, respectively. The effective conversion price was $11.00 per share. Additionally, in July 2012, the Company issued 3,030,303 shares of Series J Preferred Stock at $16.50 per share for gross proceeds of $50,000,000. Issuance costs associated with this offering were $2,204,000.
Series A Preferred Stock was originally issued at $5.00 per share; Series B Preferred Stock was issued at $5.75 per share; Series C Preferred Stock was issued at $3.56 per share; Series D Preferred Stock was issued at $4.67 per share; Series E Preferred Stock was issued at $9.76 per share; Series F Preferred Stock was issued at $11.00 per share; Series G and Series H Preferred Stock were issued at $9.79 per share; Series I Preferred Stock was issued at $11.00 per share; and Series J Preferred Stock was issued at $16.50 per share.
The following is the activity of the Preferred Stock for the six months ended June 30, 2013:
Voting
As of June 30, 2013, each holder of outstanding shares of Preferred Stock had the right to one vote for each share of Common Stock into which such Preferred Stock could then be converted. The holders of shares of Preferred Stock had full voting rights and powers equal to the voting rights and powers of shares of Common Stock and were entitled to notice of any stockholders’ meeting and voted together with the holders of Common Stock, with respect to any question upon which holders of shares of Common Stock have the right to vote, as a single class, including without limitation, actions to increase or decrease the aggregate number of authorized shares of Common Stock and/or Preferred Stock.
Dividends
As of June 30, 2013, the holders of each share of Series A, Series B, Series C, Series D, Series E, Series F, Series G, Series H, Series I and Series J Preferred Stock were entitled to receive dividends when, as, and if declared by the Company’s board of directors in the following order of preference: (i) the Series D, Series E, Series F, Series G, Series H, Series I and Series J Preferred Stock, which ranked pari passu; (ii) the Series B and Series C Preferred Stock, which ranked pari passu; (iii) the Series A Preferred Stock; and then (iv) Common Stock.
Liquidation
As of June 30, 2013, the assets of the Company legally available for distribution to stockholders were distributable in the following order of priority: (i) the holders of the shares of Series D, Series E, Series F, Series G, Series H, Series I and Series J Preferred Stock, which ranked pari passu; (ii) the holders of the shares of Series B and Series C Preferred Stock, which ranked pari passu; (iii) the holders of the shares of Series A Preferred Stock; and (iv) the holders of the shares of Common Stock. Each series of Preferred Stock was entitled to receive an amount per share equal to the greater of (1) the original issuance price for such series, plus all declared but unpaid dividends thereon, or (2) the amount that the holders of such series would receive per share of Common Stock if all shares of such series of Preferred Stock were converted to Common Stock immediately prior to such liquidation. If, upon a deemed liquidation event, the assets of the Company were insufficient to make payment in full to all holders of a series of Preferred Stock, then such assets would be distributed among the holders of such series of Preferred Stock at the time outstanding ratably in proportion to the full amount to which they would otherwise be respectively entitled. The holders of Common Stock were entitled to receive, after the payment of the liquidation preference of all Preferred Stock outstanding, the remaining assets of the Company on a pro rata basis.
Conversion
As of June 30, 2013, each issued and outstanding share of Preferred Stock was convertible into Common Stock at the holder’s option at any time after the date of issuance or automatically upon the occurrence of certain events as defined in the Company’s ninth amended and restated certificate of incorporation, at a defined conversion rate. At June 30, 2013, the number of shares of Common Stock into which one share of each series of Preferred Stock was convertible was as follows, after giving effect to the reverse stock split discussed in Note 11: the Series A Preferred Stock, 0.80; the Series B Preferred Stock, 0.85; the Series C Preferred Stock, 0.75; the Series D Preferred Stock, 0.75; the Series E Preferred Stock, 0.75; the Series F Preferred Stock, 0.77; the Series G Preferred Stock, 0.75; the Series H Preferred Stock, 0.75; the Series I Preferred Stock, 0.75; and the Series J Preferred Stock, 0.75.
The conversion price for each share of Preferred Stock was subject to adjustment upon the occurrence of certain events. The conversion price of each share of a series of Preferred Stock was adjusted if the Company issued additional shares, subject to specified exceptions, at a price lower than the then current conversion price for such series, which is measured and recognized if the contingency occurs.
On July 30, 2013, immediately prior to the consummation of the IPO, all outstanding shares of Preferred Stock automatically converted in shares of Common Stock at the applicable conversion ratio then in effect. See Note 11.
Redemption
To the extent it was then lawfully able to do so, the Company was required at any time, upon written request of the holders of at least 66.67% of the then outstanding Series A, Series B and Series C Preferred Stock collectively, or upon written request of the holders of at least a majority of the then outstanding shares of Series D, Series E and Series F Preferred Stock collectively, in each case as determined on an as-converted to Common Stock basis, to redeem the requested number of outstanding shares of Series A Preferred Stock at $5.00 per share, Series B Preferred Stock at $11.50 per share, and Series C Preferred Stock at $7.12 per share, and/or Series D, E and F Preferred Stock at $11.50 per share, as the case may be.
In addition, to the extent it was lawfully able to do so, the Company was required at any time, upon written request of the holders of at least a majority of the then outstanding shares of Series G Preferred Stock, to redeem, from the holders requesting such redemption, the requested number of outstanding shares of Series G Preferred Stock at $11.50 per share.
To the extent it would have been lawfully able to do so, the Company would have been required at any time on or after September 21, 2013, upon written request of the holders of at least a majority of the then outstanding shares of Series H Preferred Stock, to redeem, from the holders requesting such redemption, the requested number of outstanding shares of Series H Preferred Stock at $11.50 per share.
To the extent it would have been lawfully able to do so, the Company would have been required at any time on or after July 25, 2015, upon written request of the holders of at least a majority of the then outstanding shares of Series I Preferred Stock, to redeem, from the holders requesting such redemption, the requested number of outstanding shares of Series I Preferred Stock at $11.50 per share.
To the extent it would have been lawfully able to do so, the Company would have been required at any time on or after July 27, 2015, upon written request of the holders of at least a majority of the then outstanding shares of Series J Preferred Stock, to redeem, from the holders requesting such redemption, the requested number of outstanding shares of Series J Preferred Stock at $18.00 per share.
If, upon any applicable redemption date, defined as sixty days after the Company receives the written request for redemption, the funds of the Company legally available for redemption of Preferred Stock would have been insufficient to redeem the total number of shares to be redeemed on that date, those funds that were legally available would have been used to redeem the maximum possible number of shares, ratably among the holders of such shares to be redeemed. All remaining shares not redeemed would have remained outstanding until such time as additional funds become legally available for redemption.
If more than one series of Preferred Stock had been contemporaneously subject to redemption, the redemption rights of the Preferred Stock would have followed the liquidation order of priority.
As of June 30, 2013, Preferred Stock with an aggregate redemption value of $103,122,000 was redeemable. During 2013 and 2015, additional shares of Preferred Stock with an aggregate redemption value of $23,154,000 and $82,529,000, respectively, would have become redeemable at the option of the holders of Preferred Stock.
Series G Preferred Stock Warrant Transactions
The Company issued 6,128 Series G Preferred Stock warrants in connection with a Loan and Security Agreement. Additionally, the Company issued one Series G Preferred Stock warrant for every two shares of Series G Preferred Stock purchased in 2009 and 2010. The warrants were initially recorded at their fair value calculated using the Black-Scholes model, with the following weighted average assumptions: exercise price of $9.79, share price of $9.79, expected term of three years, risk-free rate of 1.52% and volatility of 85.46%. The warrants are classified as liabilities because they are exercisable for Preferred Stock, and the value of the warrants is adjusted to current fair value at each reporting period end. For the three and six months ended June 30, 2013, the Company recorded $(2,000) and $12,000, respectively, in the consolidated statements of operations and comprehensive loss related to the change in the fair value of the outstanding warrants.
There were no Series G Preferred Stock warrant transactions during the six months ended June 30, 2013. |
X | ||||||||||
- Details
|
X | ||||||||||
- Definition
Disclosure pertaining to common stock, preferred stock (conversion, dividend, and liquidation) and stockholders' deficit. No definition available.
|
Stock-Based Compensation
|
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2013
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stock-Based Compensation | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stock-Based Compensation | 7. Stock-Based Compensation
In January 2008, the board of directors approved the 2007 Equity Compensation Plan (the “2007 Plan”), which amended and restated the Company’s 1999 Stock Based Compensation Plan, which provides for the granting of incentive and nonqualified stock options and restricted stock to its employees, directors and consultants at the discretion of the board of directors. Under the 2007 Plan, the Company increased the number of shares reserved for issuance under the 2007 Plan such that the number of reserved shares is equal to 17% of the fully diluted shares calculated annually on December 10th.
Stock options may be granted with exercise prices of not less than the estimated fair value of the Company’s common stock on the date of grant and generally vest over a period of up to four years. Stock options granted under the 2007 Plan generally expire no later than ten years from the date of grant. A summary of stock option activity for the six months ended June 30, 2013 is as follows:
At June 30, 2013 and December 31, 2012, the aggregate intrinsic value of the option liability recorded was $0 and $11,967,000, respectively. During the six months ended June 30, 2013, the Company granted 314,890 options at an intrinsic value of $0 at the grant date. At certain times throughout the Company’s history, the chairman of the Company’s board of directors, who is also a significant stockholder of the Company (the “Significant Holder”), has afforded option holders the opportunity for liquidity in transactions in which options were exercised and the shares of Common Stock issued in connection therewith were simultaneously purchased by the Significant Holder (each, a “Purchase Transaction”). Because the Company has established a pattern of providing cash settlement alternatives for option holders, the Company has accounted for its stock-based compensation awards as liability awards, the fair value of which is then re-measured at each balance sheet date. Upon the exercise of stock options from January 1, 2013 through April 23, 2013, stock option liabilities of $38,000 were reclassified to stockholders’ deficit.
On April 23, 2013, the Company distributed a notification letter to all equity award holders under the 2007 Plan advising them that Purchase Transactions will no longer occur, unless, at the time of a Purchase Transaction, the option holder has held the Common Stock issued upon exercise of options for a period of greater than six months prior to selling such Common Stock to the Significant Holder and that any such sale to the Significant Holder would be at the fair value of the Common Stock on the date of such sale. Based on these new criteria for Purchase Transactions, the Company remeasured options outstanding under the 2007 Plan as of April 23, 2013 to their intrinsic value and reclassified such options from liabilities to stockholders’ deficit within the Company’s consolidated balance sheets, which amounted to $14,482,000.
A roll forward of the stock option liability balance for the six months ended June 30, 2013 is as follows:
The Company accounts for all stock-based payments made after April 23, 2013 to employees and directors using an option pricing model for estimating fair value. Accordingly, stock-based compensation expense is measured based on the estimated fair value of the awards on the date of grant, net of forfeitures. Compensation expense is recognized for the portion that is ultimately expected to vest over the period during which the recipient renders the required services to the Company using the straight-line single option method. In accordance with authoritative guidance, the fair value of non-employee stock based awards is re-measured as the awards vest, and the resulting increase in fair value, if any, is recognized as expense in the period the related services are rendered.
The Company estimates the fair value of its share-based awards to employees and directors using the Black-Scholes option pricing model. The Black-Scholes model requires the input of highly complex and subjective assumptions, including (a) the expected stock price volatility, (b) the calculation of the expected term of the award, (c) the risk free interest rate and (d) expected dividends. Due to the Company’s limited operating history and a lack of company specific historical and implied volatility data, the Company has based its estimate of expected volatility on the historical volatility of a group of similar companies that are publicly traded. When selecting these public companies on which it has based its expected stock price volatility, the Company selected companies with comparable characteristics to it, including enterprise value, risk profiles, position within the industry, and with historical share price information sufficient to meet the expected life of the stock-based awards. The historical volatility data was computed using the daily closing prices for the selected companies’ shares during the equivalent period of the calculated expected term of the stock-based awards. Due to its lack of sufficient historical data, the Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of its own stock price becomes available. The Company has estimated the expected life of its employee stock options using the “simplified” method, whereby, the expected life equals the arithmetic average of the vesting term and the original contractual term of the option. The risk-free interest rates for periods within the expected life of the option are based on the U.S. Treasury yield curve in effect during the period the options were granted. The Company has never paid, and does not expect to pay dividends in the foreseeable future.
Stock-based compensation expense includes stock options granted to employees and non-employees and has been reported in the Company’s statements of operations and comprehensive loss in either research and development expenses or general and administrative expenses depending on the function performed by the optionee. No net tax benefits related to the stock-based compensation costs have been recognized since the Company’s inception.
During the period from April 23, 2013 through June 30, 2013, the Company granted options to purchase 3,450 shares of its common stock at an exercise price of $14.74 per share. The Company recorded $33,000 of compensation expense related to these options. The fair value of these nonemployee options was estimated using the Black-Scholes option pricing model with the following weighted-average assumptions: no dividend yield, volatility of 81.32%, maximum contractual life of 5.0 years, and a risk-free interest rate of 0.98%.
The Company recognized stock-based compensation expense as follows for the three and six months ended June 30, 2013 and 2012:
As of June 30, 2013, there was $2,351,000 of unrecognized compensation expense related to unvested stock options, which is expected to be recognized over a weighted-average period of approximately 2.08 years. The Company accounts for stock options issued to nonemployees using a fair value approach. The compensation costs of these arrangements are subject to re-measurement over the vesting terms as earned.
Information with respect to stock options outstanding and exercisable at June 30, 2013 is as follows:
|
X | ||||||||||
- Details
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
License and Collaboration Agreements
|
6 Months Ended |
---|---|
Jun. 30, 2013
|
|
License and Collaboration Agreements | |
License and Collaboration Agreements | 8. License and Collaboration Agreements
Baxter Agreement
In September 2012, the Company entered into a development and license agreement with Baxter granting Baxter an exclusive, royalty-bearing license for the research, development, commercialization and manufacture (in specified instances) of rigosertib in all therapeutic indications in Europe (the “Baxter Territory”). Baxter is a stockholder in the Company and invested in Series J Preferred Stock issued in July 2012.
Under the terms of the agreement, the Company is initially required to perform research and development to advance three initial rigosertib indications, rigosertib intravenous (“rigosertib IV”) in higher risk myelodysplastic syndrome (“MDS”) patients, rigosertib IV in pancreatic cancer patients and rigosertib oral (“rigosertib Oral”) in lower risk MDS patients, through phase 3, phase 3 and phase 2 clinical trials, respectively.
If an additional phase 3 clinical trial beyond the current phase 3 clinical trial in process for rigosertib IV in higher risk MDS patients is required to obtain marketing approval in the Baxter Territory, the Company could require Baxter to fund a percentage of the costs of such additional trial up to a specified maximum. At the completion of the current phase 3 trial for rigosertib IV in pancreatic cancer and the current phase 2 trial for rigosertib Oral in lower risk MDS patients and the review of the resulting data and findings, the Company and Baxter will decide whether or not to pursue further development of rigosertib for these indications. If the Company and Baxter mutually agree to progress the development of rigosertib IV in pancreatic cancer patients and rigosertib Oral in lower risk MDS patients, then certain milestone payments will be payable to the Company, and the Company will be required to use its commercially reasonable efforts to progress the development of rigosertib for these indications to a drug approval application in the Baxter Territory. The Company and Baxter will work together for potential future rigosertib indications, beyond the initial indications noted above. Generally, if Baxter chooses to participate in the development of additional indications, Baxter will be responsible for a percentage of all research and development costs and expenses and the Company could earn additional milestone payments. Baxter has full responsibility for all commercialization activities for the product in the Baxter Territory, at Baxter’s sole cost and expense.
The Company and Baxter have agreed to negotiate a supply agreement under terms satisfactory to both parties whereby the Company will supply Baxter with Baxter’s required levels of product to support commercialization efforts in the Baxter Territory. Baxter also has the right to engage third parties for the manufacture and supply of its requirements for the licensed product.
Under the terms of the agreement, Baxter made an upfront payment of $50,000,000. The Company is eligible to receive pre-commercial milestone payments of up to an aggregate of $512,500,000 if specified development and regulatory milestones are achieved. The potential pre-commercial development milestone payments to us include the following:
· $50,000,000 for successful completion of a phase 3 clinical trial for rigosertib IV in higher risk MDS patients;
· $25,000,000 for each of the two joint decisions to proceed with the development of rigosertib for certain indications specified in the arrangement with Baxter; and
· $25,000,000 for each drug approval application filed for indications specified in the arrangement with Baxter.
The Company may also receive up to $337,500,000 in milestone payments for regulatory approvals of the three rigosertib indications specified in the arrangement with Baxter, each of which may be up to and in excess of $100,000,000. The Company is also potentially eligible to receive an additional $20,000,000 pre-commercial milestone payment related to the timing of regulatory approval for rigosertib IV in higher risk MDS patients in Europe. In addition to these pre-commercial milestones, the Company is eligible to receive up to an aggregate of $250,000,000 in milestone payments based on Baxter’s achievement of pre-specified threshold levels of annual net sales of rigosertib. The Company will also be entitled to receive royalties at percentage rates ranging from the low-teens to the low-twenties on net sales of rigosertib by Baxter in the Baxter Territory.
The agreement with Baxter will remain in effect until the expiration of all applicable royalty terms and satisfaction of all payment obligations in each licensed country, unless terminated earlier due to the uncured material breach or bankruptcy of a party, force majeure, or in the event of a specified commercial failure. The Company may terminate the agreement in the event that Baxter brings a challenge against it in relation to the licensed patents. Baxter may terminate the agreement without cause commencing after a specified period of time from the execution of the agreement.
The Company has determined that the deliverables under the Baxter agreement include the exclusive, royalty-bearing, sublicensable license to rigosertib and the research and development services to be performed by the Company. The Company concluded that the license had standalone value to Baxter and was separable from the research and development services because the license is sublicensable, there are no restrictions as to Baxter’s use of the license and Baxter has significant research capabilities in this field.
In determining the separate units of accounting, the Company considered applicable accounting guidance and noted that in an arrangement with multiple deliverables, the delivered item or items shall be considered a separate unit of accounting if the delivered item or items have value to the customer on a stand-alone basis. The item or items have value on a stand-alone basis if they are sold separately by any vendor or the customer could resell the delivered item(s) on a stand-alone basis. In the context of a customer’s ability to resell the delivered item(s), this criterion does not require the existence of an observable market for the deliverable(s).
The Baxter agreement allows Baxter to sublicense rigosertib and its ability to sublicense is not contingent on the approval or right of first refusal by the Company. The Company determined that Baxter’s ability to sublicense the intellectual property to others demonstrates that the license has stand-alone value. In addition, at the time of entering into the Baxter agreement in September 2012, the rigosertib program was in a phase 3 clinical trial for higher risk MDS, a phase 3 clinical trial for pancreatic cancer and a phase 2 trial for lower risk MDS. The protocols for the clinical trials had been written and provided to Baxter and a Special Protocol Assessment (“SPA”) had already been granted to the Company by the U.S. Food and Drug Administration (“FDA”) for higher risk MDS. These later stage clinical trials, where protocols have been prepared and trials are in process, can be completed more easily by entities other than the Company, as compared to earlier stage clinical trials. The remaining services to be performed by the Company are not proprietary and could be performed by other qualified parties. For example, the Company relies on clinical research organizations (“CROs”) to complete the clinical trials, and Baxter could engage the same or similar CROs to complete the trials on its behalf. Although Baxter is not performing development activities related to rigosertib, Baxter possesses the internal expertise (or a vendor could be hired) to complete the efforts under the rigosertib programs without further assistance from the Company.
Baxter develops, manufactures and markets products that save and sustain the lives of people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions. As a global, diversified healthcare company, Baxter applies a unique combination of expertise in medical devices, pharmaceuticals and biotechnology to create products that advance patient care worldwide. Baxter employs over 50,000 people, with significant revenues and expenditures for research and development. Baxter has expertise in completing clinical trials, assessing clinical trial results and preparing regulatory filings and has also developed and obtained regulatory and marketing approval in Europe for numerous products used to treat hematologic conditions. Baxter has expertise in rare hematologic conditions, and the Company believes that rigosertib is a natural complement to Baxter’s existing treatments for patients with these conditions.
Baxter has the rights and full access to past and future intellectual information in order to obtain regulatory approval of rigosertib in Europe. In connection with the Baxter agreement, the Company licensed to Baxter all information and all patents controlled by the Company necessary for the development, manufacture, use and sale of rigosertib and all present and future formulations and dosages in all present and future therapeutic indications in the licensed territory.
Accordingly, given Baxter’s ability to sublicense under the agreement and its ability internally or with outside help to conduct the ongoing development efforts, the Company concluded that the license has stand-alone value. In order to determine if the license can be treated as a separate unit of accounting, the Company also considered whether there is a general right of return associated with the license. The $50,000,000 upfront payment received by the Company is non-refundable; therefore, there is no right of return for the license. As a result, the Company concluded that the license is a separate unit of accounting.
The Company was not able to establish vendor-specific objective evidence of selling price or third-party evidence for either the license or the research and development services and instead allocated the arrangement consideration between the license and research and development services based on their relative selling prices using best estimate of selling price (“BESP”). Management developed the BESP of the license using a discounted cash flow model, taking into consideration assumptions including the development and commercialization timeline, discount rate and probability of success. Management utilized a third party valuation specialist to assist with the determination of BESP of the license. Management estimated the selling price of the research and development services using third party costs and a discounted cash flow model. The estimated selling prices utilized assumptions including internal estimates of research and development personnel needed to perform the research and development services; and estimates of expected cash outflows to third parties for services and supplies over the expected period that the services will be performed.
The key assumptions in these models included the following market conditions and entity-specific factors: (a) the specific rights provided under the license, (b) the stage of development of rigosertib and estimated remaining development and commercialization timelines, (c) the probability of successfully developing and commercializing rigosertib, (d) the market size including the associated sales figures which generate royalty revenue, (e) cost of goods sold, which was assumed to be a specified percentage of revenues based on estimated cost of goods sold of a typical oncology product, (f) sales and marketing costs, which were based on the costs required to field an oncology sales force and marketing group, including external costs required to promote an oncology product, (g) the expected product life of rigosertib assuming commercialization and (h) the competitive environment. The Company utilized a discount rate of 16%, representing the cost of capital derived from returns on equity for comparable companies.
Based on management’s analyses, it was determined that the BESP of the license was $120,000,000 and the BESP of the research and development services was $20,600,000. As noted above, the Company received an up-front payment of $50,000,000 under the Baxter agreement, which represents the allocable agreement consideration. Based on the respective BESPs, this payment was allocated $42,400,000 to the license and $7,600,000 to the research and development services. Since the delivery of the license occurred upon the execution of the Baxter agreement and there was no general right of return, $42,400,000 of the $50,000,000 upfront payment was recognized upon the execution of the Baxter agreement. The portion allocated to research and development services is being recognized over the period of performance on a proportional performance basis through March 31, 2014. Management estimated the period of performance to be the period necessary for completion of the non-contingent obligations to perform research and development services required to advance the three formulations of rigosertib described above. For the three and six months ended June 30, 2013, the Company recognized $990,000 and $1,456,000, respectively, of research and development revenue under the Baxter agreement.
The Company and Baxter have agreed to establish a joint committee to facilitate the governance and oversight of the parties’ activities under the agreements. Management considered whether participation on the joint committee may be a deliverable and determined that it was not a deliverable. Had management considered participation on the joint committee as a deliverable, it would not have had a material impact on the accounting for the arrangement based on the analysis of the estimated selling price of such participation.
As noted above, in July 2012, Baxter purchased Series J Preferred Stock. Because the Series J Preferred Stock was acquired within several months of the Baxter development and license agreement, management considered whether the Preferred Stock was issued at fair value and if not, whether the consideration received for the Preferred Stock ($50,000,000) or for the collaboration and license agreement ($50,000,000) should be allocated in the financial statements in a manner differently than the prices stated in the agreements. Management, with the assistance of an outside valuation specialist, determined that the price paid by Baxter for the Series J Preferred Stock approximated its fair value, and therefore the consideration received under the agreements was allocated in accordance with terms of the individual agreements.
SymBio Agreement
In July 2011, the Company entered into a license agreement with SymBio, as subsequently amended, granting SymBio an exclusive, royalty-bearing license for the development and commercialization of rigosertib in Japan and Korea. Under the SymBio license agreement, SymBio is obligated to use commercially reasonable efforts to develop and obtain market approval for rigosertib inside the licensed territory and the Company has similar obligations outside of the licensed territory. The Company has also entered into an agreement with SymBio providing for it to supply SymBio with development-stage product. Under the SymBio license agreement, the Company also agreed to supply commercial product to SymBio under specified terms that will be included in a commercial supply agreement to be negotiated prior to the first commercial sale of rigosertib. The supply of development-stage product and the supply of commercial product will be at the Company’s cost plus a defined profit margin. Sales of development-stage product have been de minimis. The Company has additionally granted SymBio a right of first negotiation to license or obtain the rights to develop and commercialize compounds having a chemical structure similar to rigosertib in the licensed territory.
Under the terms of the SymBio license agreement, the Company received an upfront payment of $7,500,000. The Company is eligible to receive milestone payments of up to an aggregate of $33,000,000 from SymBio upon the achievement of specified development and regulatory milestones for specified indications. Of the development milestones, $3,000,000 is due after enrollment of the first patient in the event a decision is made, after the Company’s interim analysis, to start a phase 3 clinical trial of rigosertib IV in combination with gemcitabine for pancreatic cancer patients in the United States. Of the regulatory milestones, $5,000,000 is due upon receipt of marketing approval in the United States for rigosertib IV in higher risk MDS patients, $3,000,000 is due upon receipt of marketing approval in Japan for rigosertib IV in higher risk MDS patients, $5,000,000 is due upon receipt of marketing approval in the United States for rigosertib Oral in lower risk MDS patients, $5,000,000 is due upon receipt of marketing approval in Japan for rigosertib Oral in lower risk MDS patients, $5,000,000 is due upon receipt of marketing approval in the United States for rigosertib IV in combination with gemcitabine in pancreatic cancer patients, and $3,000,000 is due upon receipt of marketing approval in Japan for rigosertib IV in combination with gemcitabine for pancreatic cancer patients. Furthermore, upon receipt of marketing approval in the United States and Japan for an additional indication of rigosertib, which we are currently not pursuing, an aggregate of $4,000,000 would be due. In addition to these pre-commercial milestones, the Company is eligible to receive tiered milestone payments based upon annual net sales of rigosertib by SymBio of up to an aggregate of $30,000,000. Further, under the terms of the SymBio license agreement, SymBio will make royalty payments to the Company at percentage rates ranging from the mid-teens to 20% based on net sales of rigosertib by SymBio.
Royalties will be payable under the SymBio agreement on a country-by-country basis in the licensed territory, until the later of the expiration of marketing exclusivity in those countries, a specified period of time after first commercial sale of rigosertib in such country, or the expiration of all valid claims of the licensed patents covering rigosertib or the manufacture or use of rigosertib in such country. If no valid claim exists covering the composition of matter of rigosertib or the use of or treatment with rigosertib in a particular country before the expiration of the royalty term, and specified competing products achieve a specified market share percentage in such country, SymBio’s obligation to pay the Company royalties will continue at a reduced royalty rate until the end of the royalty term. In addition, the applicable royalties payable to the Company may be reduced if SymBio is required to pay royalties to third-parties for licenses to intellectual property rights necessary to develop, use, manufacture or commercialize rigosertib in the licensed territory. The license agreement with SymBio will remain in effect until the expiration of the royalty term. However, the SymBio license agreement may be terminated earlier due to the uncured material breach or bankruptcy of a party, or force majeure. If SymBio terminates the license agreement in these circumstances, its licenses to rigosertib will survive, subject to SymBio’s milestone and royalty obligations, which SymBio may elect to defer and offset against any damages that may be determined to be due from the Company. In addition, the Company may terminate the license agreement in the event that SymBio brings a challenge against it in relation to the licensed patents, and SymBio may terminate the license agreement without cause by providing the Company with written notice within a specified period of time in advance of termination.
The Company determined that the deliverables under the SymBio agreement include the exclusive, royalty-bearing, sublicensable license to rigosertib, the research and development services to be provided by the Company and its obligation to serve on a joint committee. The Company concluded that the license did not have standalone value to SymBio and was not separable from the research and development services, because of the uncertainty of SymBio’s ability to develop rigosertib in the SymBio territory on its own and the uncertainty of SymBio’s ability to sublicense rigosertib and recover a substantial portion of the original upfront payment of $7,500,000 paid by SymBio to the Company.
The supply of rigosertib for SymBio’s commercial requirements is contingent upon the receipt of regulatory approvals to commercialize rigosertib in Japan and Korea. Because the Company’s commercial supply obligation was contingent upon the receipt of future regulatory approvals, and there were no binding commitments or firm purchase orders pending for commercial supply at or near the execution of the agreement, the commercial supply obligation is deemed to be contingent and is not valued as a deliverable under the SymBio agreement. If SymBio orders the supplies from the Company, the Company expects the pricing for this supply to equal its third-party manufacturing cost plus a pre-negotiated percentage, which will not result in a significant incremental discount to market rates.
Due to the lack of standalone value for the license, research and development services, and joint committee obligation, the upfront payment is being recognized ratably using the straight line method through December 2027, the expected term of the agreement. For each of the three and six months ended June 30, 2013 and 2012, the Company recognized revenues of $113,000 and $227,000, respectively, under this agreement. In addition, the Company recognized revenues related to the supply agreement with SymBio in the amounts of $0 and $10,000 for the three months ended June 30, 2013 and 2012, respectively, and $24,000 and $10,000 for the six months ended June 30, 2013 and 2012, respectively. |
X | ||||||||||
- Details
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
Joint Venture
|
6 Months Ended |
---|---|
Jun. 30, 2013
|
|
Joint Venture | |
Joint Venture | 9. Joint Venture
In December 2012, the Company agreed to create a joint venture with GVK Biosciences Private Limited (‘‘GVK BIO’’), a private limited company located in India. The resulting joint venture, GBO, LLC, a Delaware limited liability company (‘‘GBO’’), was formed on April 1, 2013. The purpose of GBO is to collaborate on and develop two new programs through filing of an investigational new drug application and/or conducting proof of concept studies using the Company’s technology platform. GBO has not commenced operations as of June 30, 2013. |
X | ||||||||||
- Details
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
Related-Party Transactions
|
6 Months Ended |
---|---|
Jun. 30, 2013
|
|
Related-Party Transactions | |
Related-Party Transactions | 10. Related-Party Transactions
The Company has entered into a research agreement, as subsequently amended, with the Mount Sinai School of Medicine (“Mount Sinai”), with which a member of its board of directors and a significant stockholder is affiliated. Mount Sinai is undertaking research on behalf of the Company on the terms set forth in the agreements. Mount Sinai, in connection with the Company, will prepare applications for patents generated from the research. Results from all projects will belong exclusively to Mount Sinai, but the Company will have an exclusive option to license any inventions. Payments to Mount Sinai for the three months ended June 30, 2013 and 2012 were $198,000 and $285,000, respectively and for the six months ended June 30, 2013 and 2012 were $225,000 and $469,000, respectively. At June 30, 2013 and 2012, the Company owed Mount Sinai $295,000 and $0, respectively, which is included in accounts payable on the consolidated balance sheets.
The Company outsources the synthesis of some of its chemical compounds to vendors in the United States and in foreign countries. A supplier, of which a member of the Company’s board of directors and a significant stockholder is an owner, produces one of these compounds under contract. The Company’s aggregate payments for these services for the three months ended June 30, 2013 and 2012 were $0 and $0, respectively and for the six months ended June 30, 2013 and 2012 were $107,000 and $52,500, respectively. At June 30, 2013 and 2012, the Company owed this supplier $0 and $9,000, respectively, which is included in accounts payable on the consolidated balance sheets.
The Company purchases chemical compounds from corporations owned by a former member of its board of directors. The Company’s aggregate payments to these suppliers for the three months ended June 30, 2013 and 2012 were $212,000 and $173,000, respectively and for the six months ended June 30, 2013 and 2012 were $240,000 and $452,000, respectively. At June 30, 2013 and 2012, the Company owed this supplier $31,000 and $0, respectively, which is included in accounts payable on the consolidated balance sheets. The Company also rents office space in Pennington, New Jersey from a corporation related to these suppliers and affiliated with the former member of our board of directors. |
X | ||||||||||
- Details
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
Subsequent Event
|
6 Months Ended |
---|---|
Jun. 30, 2013
|
|
Subsequent Event | |
Subsequent Event | 11. Subsequent Event
On July 24, 2013, the Company’s Registration Statement was declared effective by the SEC, and on July 25, 2013, the Company’s Common Stock began trading on the NASDAQ Global Market under the symbol ONTX.
On July 30, 2013, immediately prior to the consummation of the IPO, all outstanding shares of Preferred Stock automatically converted into shares of Common Stock at the applicable conversion ratio then in effect. As a result of the conversion, as of July 30, 2013, the Company had no shares of Preferred Stock outstanding.
On July 30, 2013, the Company completed the IPO. The Company received net proceeds of $79,600,000 from the IPO, net of underwriting discounts and commissions and other estimated offering expenses.
In preparation for the IPO, the Company’s board of directors and stockholders approved a one-for-1.333 reverse stock split of the Company’s Common Stock. The reverse stock split became effective on July 17, 2013. All Common Stock share and per share amounts in the condensed consolidated financial statements and notes thereto have been retroactively adjusted for all periods presented to give effect to this reverse stock split, including reclassifying an amount equal to the reduction in par value of common stock to additional paid-in capital. The reverse stock split did not result in a retroactive adjustment of share amounts for the Preferred Stock. In addition, in July 2013, the Company’s board of directors and stockholders approved an amendment of the Company’s certificate of incorporation to, among other things, change the definition of a designated public offering to remove the per share price requirement and to set the threshold at gross proceeds to the Company of at least $25.0 million. Further, in July 2013, the Company’s board of directors and stockholders approved, effective immediately prior to the listing of its Common Stock on the NASDAQ Global Market, the 2013 Equity Compensation Plan (the ‘‘2013 Plan’’). Under the 2013 Plan, the Company may grant incentive stock options, non-statutory stock options, stock appreciation rights, restricted stock, restricted stock units, deferred share awards, performance awards and other equity-based awards to employees, directors and consultants. The Company initially reserved 6,107,831 shares of common stock for issuance, subject to adjustment as set forth in the 2013 Plan, of which 3,315,662 shares of common stock will be available for future issuance. On July 25, 2013, in conjunction with the IPO, the Company issued 485,500 stock options. |
X | ||||||||||
- Details
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
Summary of Significant Accounting Policies (Policies)
|
6 Months Ended |
---|---|
Jun. 30, 2013
|
|
Summary of Significant Accounting Policies | |
Basis of Presentation | Basis of Presentation
The condensed consolidated financial statements are prepared in conformity with accounting principles generally accepted in the United States (“GAAP”) for interim financial information. Certain information and footnotes normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to the rules and regulations of the Securities and Exchange Commission. The financial statements include the consolidated accounts of the Company and its wholly-owned subsidiary, Onconova Europe GmbH. All significant intercompany transactions have been eliminated. |
Unaudited Interim Financial Information | Unaudited Interim Financial Information
The accompanying condensed consolidated balance sheet as of June 30, 2013, the condensed consolidated statements of operations and comprehensive loss for the three and six months ended June 30, 2013 and 2012, the condensed consolidated statements of redeemable convertible preferred stock and stockholders’ deficit and the condensed consolidated statements of cash flows for the six months ended June 30, 2013 and 2012 are unaudited. The interim unaudited condensed consolidated financial statements have been prepared on the same basis as the annual audited consolidated financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary for the fair statement of the Company’s financial position as of June 30, 2013 and the results of its operations, its comprehensive loss and its cash flows for the six months ended June 30, 2013 and 2012. The financial data and other information disclosed in these notes related to the six months ended June 30, 2013 and 2012 are unaudited. The results for the six months ended June 30, 2013 are not necessarily indicative of results to be expected for the year ending December 31, 2013, any other interim periods, or any future year or period. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the notes thereto for the year ended December 31, 2012 included in the Company’s final prospectus filed on July 25, 2013 with the Securities and Exchange Commission (the “SEC”) pursuant to Rule 424(b)(4) of the Securities Act of 1933, as amended (the “Securities Act”). |
Segment Information | Segment Information
Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business in one segment, which is the identification and development of oncology therapeutics. |
Significant Accounting Policies | Significant Accounting Policies
The Company’s significant accounting policies are disclosed in the audited consolidated financial statements for the year ended December 31, 2012 included in the Company’s final prospectus filed on July 25, 2013 with the SEC pursuant to Rule 424(b)(4) of the Securities Act. Since the date of such financial statements, there have been no changes to the Company’s significant accounting policies. |
Foreign Currency Translation | Foreign Currency Translation
The reporting currency of the Company and its U.S. subsidiary is the U.S. dollar. The functional currency of the Company’s non-U.S. subsidiary is the local currency. Assets and liabilities of the foreign subsidiary are translated into U.S. dollars based on exchange rates at the end of the period. Revenues and expenses are translated at average exchange rates during the reporting period. Gains and losses arising from the translation of assets and liabilities are included as a component of accumulated other comprehensive income. Gains and losses resulting from foreign currency transactions are reflected within the Company’s results of operations. The Company has not utilized any foreign currency hedging strategies to mitigate the effect of its foreign currency exposure. |
Deferred Initial Public Offering Costs | Deferred Initial Public Offering Costs
Deferred IPO costs as of June 30, 2013, consisting of legal, accounting, printing and filing fees incurred in the preparation of the Company’s Registration Statement on Form S-1 were capitalized. The deferred costs are included in prepaid expenses and other current assets on the consolidated balance sheets. See Note 5. The deferred offering costs were offset against the IPO proceeds upon the completion of the offering in July 2013. |
Recent Accounting Pronouncements | Recent Accounting Pronouncements
In February 2013, the Financial Accounting Standards Board (the “FASB”) amended its guidance to require an entity to present the effect of certain significant reclassifications out of accumulated other comprehensive income on the respective line items in net income. The new accounting guidance does not change the items that must be reported in other comprehensive income or when an item of other comprehensive income must be reclassified to net income. The guidance is effective prospectively for fiscal years beginning after December 15, 2012. The Company adopted these new provisions for the quarter beginning January 1, 2013. As the guidance requires additional presentation only, there was no impact to the Company’s consolidated financial position, results of operations or cash flows.
In July 2013, the FASB issued guidance clarifying that an unrecognized tax benefit, or a portion of an unrecognized tax benefit, should be presented in the financial statements as a reduction to a deferred tax asset for a net operating loss carryforward, a similar tax loss, or a tax credit carryforward if such settlement is required or expected in the event the uncertain tax benefit is disallowed. In situations where a net operating loss carryforward, a similar tax loss, or a tax credit carryforward is not available at the reporting date under the tax law of the applicable jurisdiction or the tax law of the jurisdiction does not require, and the entity does not intend to use, the deferred tax asset for such purpose, the unrecognized tax benefit should be presented in the financial statements as a liability and should not be netted with the deferred tax asset. The guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2013. Early adoption is permitted. The amendments should be applied prospectively to all unrecognized tax benefits that exist at the effective date. Retrospective application is permitted. The Company is currently evaluating the impact that adoption will have on the determination or reporting of its financial results. |
X | ||||||||||
- Definition
Disclosure of accounting policy for significant accounting policies. No definition available.
|
X | ||||||||||
- Definition
Disclosure of accounting policy for unaudited interim financial information. No definition available.
|
X | ||||||||||
- Details
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
Fair Value Measurements (Tables)
|
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2013
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair Value Measurements | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of financial assets and liabilities measured at fair value on a recurring basis | The following fair value hierarchy table presents information about the Company’s financial assets and liabilities measured at fair value on a recurring basis as of June 30, 2013 and December 31, 2012:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of reconciliation of liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) | The following table presents a reconciliation of the Company’s liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) for the six months ended June 30, 2013:
|
X | ||||||||||
- Details
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
Net Loss Per Share of Common Stock (Tables)
|
6 Months Ended | ||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2013
|
|||||||||||||||||||||||||||||||||||||
Net Loss Per Share of Common Stock | |||||||||||||||||||||||||||||||||||||
Schedule of antidilutive securities which have been excluded from the computation of diluted weighted average shares outstanding | The following potentially dilutive securities outstanding at June 30, 2013 and 2012 have been excluded from the computation of diluted weighted average shares outstanding, as they would be antidilutive:
|
X | ||||||||||
- Details
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
Balance Sheet Detail (Tables)
|
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2013
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Balance Sheet Detail | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of prepaid expenses and other current assets |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of property and equipment |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of accrued expenses and other current liabilities |
|
X | ||||||||||
- Definition
Tabular disclosure of the components of accrued expenses and other current liabilities. No definition available.
|
X | ||||||||||
- Definition
Tabular disclosure of the carrying amounts of prepaid expenses and other current assets. No definition available.
|
X | ||||||||||
- Details
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
Preferred Stock and Stockholders' Deficit (Tables)
|
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2013
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Preferred Stock and Stockholders' Deficit | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of composition of share capital |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of activity of the Preferred Stock | The following is the activity of the Preferred Stock for the six months ended June 30, 2013:
|
X | ||||||||||
- Details
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
Stock-Based Compensation (Tables)
|
6 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2013
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stock-Based Compensation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of shares reserved for issuance under the 2007 Plan |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of stock option activity | A summary of stock option activity for the six months ended June 30, 2013 is as follows:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of roll forward of the stock option liability | A roll forward of the stock option liability balance for the six months ended June 30, 2013 is as follows:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of stock-based compensation expense | The Company recognized stock-based compensation expense as follows for the three and six months ended June 30, 2013 and 2012:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of information with respect to stock options outstanding and exercisable | Information with respect to stock options outstanding and exercisable at June 30, 2013 is as follows:
|
X | ||||||||||
- Definition
Tabular disclosure of the number of shares reserved for issuance under the share-based compensation plan. No definition available.
|
X | ||||||||||
- Definition
Tabular disclosure of the change in stock options liability. No definition available.
|
X | ||||||||||
- Details
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
X | ||||||||||
- Definition
Represents the number of clinical-stage product candidates. No definition available.
|
X | ||||||||||
- Definition
Represents the number of preclinical programs. No definition available.
|
X | ||||||||||
- Definition
Represents the number of series denominations of preferred stock. No definition available.
|
X | ||||||||||
- Definition
The number of shares issued pursuant to an option granted to the underwriters to cover over-allotments during the period. No definition available.
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
X | ||||||||||
- Details
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
X | ||||||||||
- Details
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
Summary of Significant Accounting Policies (Details)
|
6 Months Ended |
---|---|
Jun. 30, 2013
item
|
|
Segment Information | |
Number of operating segments | 1 |
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
X | ||||||||||
- Details
|
X | ||||||||||
- Definition
Represents the number of companies of which average historical share price trading data used for estimation of volatility. No definition available.
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
X | ||||||||||
- Details
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
Fair Value Measurements (Details 2) (Warrants, USD $)
|
6 Months Ended |
---|---|
Jun. 30, 2013
|
|
Warrants
|
|
Reconciliation of the warrant liability measured at fair value | |
Balance at the beginning of the period | $ 62,000 |
Change in fair value upon re-measurement | (12,000) |
Balance at the end of the period | 50,000 |
Additional disclosures | |
Transfer of assets from level 1 to level 2 | 0 |
Transfer of assets from level 2 to level 1 | 0 |
Transfer of liabilities from level 1 to level 2 | 0 |
Transfer of liabilities from level 2 to level 1 | $ 0 |
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
X | ||||||||||
- Details
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
X | ||||||||||
- Details
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
X | ||||||||||
- Details
|
Balance Sheet Detail (Details) (USD $)
|
Jun. 30, 2013
|
Dec. 31, 2012
|
---|---|---|
Prepaid expenses and other current assets: | ||
Research and development | $ 2,399,000 | $ 1,429,000 |
Deferred initial public offering costs | 2,285,000 | |
Other | 1,183,000 | 296,000 |
Total | 5,867,000 | 1,725,000 |
Property and equipment: | ||
Property and equipment | 2,284,000 | 1,811,000 |
Accumulated depreciation | (1,555,000) | (1,348,000) |
Total | 729,000 | 463,000 |
Accrued expenses and other current liabilities: | ||
Research and development | 3,972,000 | 3,521,000 |
Payroll | 818,000 | 247,000 |
Other | 548,000 | 157,000 |
Accrued expenses and other current liabilities | $ 5,338,000 | $ 3,925,000 |
X | ||||||||||
- Details
|
X | ||||||||||
- Definition
Total of the carrying values, as of the balance sheet date, of obligations incurred through that date and payable for obligations related to accrued expenses and other costs not separately disclosed in the balance sheet. It is used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). No definition available.
|
X | ||||||||||
- Definition
Carrying value as of the balance sheet date of obligations incurred through that date and payable for research and development. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). No definition available.
|
X | ||||||||||
- Definition
Amount of asset related to consideration paid in advance for research and development that provides economic benefits within a future period of one year or the normal operating cycle, if longer. No definition available.
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
X | ||||||||||
- Details
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
X | ||||||||||
- Details
|
Preferred Stock and Stockholders' Deficit (Details) (USD $)
|
3 Months Ended | 6 Months Ended | 0 Months Ended | 3 Months Ended | 6 Months Ended | 1 Months Ended | 6 Months Ended | 6 Months Ended | 6 Months Ended | 6 Months Ended | 1 Months Ended | 6 Months Ended | |||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2013
|
Jun. 30, 2012
|
Jun. 30, 2013
item
|
Jun. 30, 2012
|
Dec. 31, 2012
|
Jul. 17, 2013
Subsequent event
|
Jul. 30, 2013
Subsequent event
|
Jun. 30, 2013
Series G Preferred Stock Warrant
|
Jun. 30, 2013
Series G Preferred Stock Warrant
|
Jul. 31, 2012
Convertible promissory notes
|
Jun. 30, 2013
Preferred stock
|
Dec. 31, 2012
Preferred stock
|
Dec. 31, 2015
Preferred stock
Expected
|
Dec. 31, 2013
Preferred stock
Expected
|
Jun. 30, 2013
Preferred stock
Minimum
item
|
Jun. 30, 2013
Series A Preferred Stock
|
Dec. 31, 2012
Series A Preferred Stock
|
Jun. 30, 2013
Series B Preferred Stock
|
Dec. 31, 2012
Series B Preferred Stock
|
Jun. 30, 2013
Series C Preferred Stock
|
Dec. 31, 2012
Series C Preferred Stock
|
Jun. 30, 2013
Series D Preferred Stock
|
Dec. 31, 2012
Series D Preferred Stock
|
Jun. 30, 2013
Series E Preferred Stock
|
Dec. 31, 2012
Series E Preferred Stock
|
Jun. 30, 2013
Series F Preferred Stock
|
Dec. 31, 2012
Series F Preferred Stock
|
Jun. 30, 2013
Series G Preferred Stock
|
Dec. 31, 2012
Series G Preferred Stock
|
Jun. 30, 2013
Series H Preferred Stock
|
Dec. 31, 2012
Series H Preferred Stock
|
Jun. 30, 2013
Series I Preferred Stock
|
Dec. 31, 2012
Series I Preferred Stock
|
Jul. 31, 2012
Series I Preferred Stock
Convertible promissory notes
|
Jul. 31, 2012
Series J Preferred Stock
|
Jun. 30, 2013
Series J Preferred Stock
|
Dec. 31, 2012
Series J Preferred Stock
|
|
Preferred stock and stockholders' deficit | |||||||||||||||||||||||||||||||||||||
Gross proceeds from issuance of shares of preferred stock | $ 50,000,000 | ||||||||||||||||||||||||||||||||||||
Shares of preferred stock issued | 16,912,199 | 16,912,199 | 16,912,199 | 16,912,199 | 16,912,199 | 107,000 | 107,000 | 1,107,189 | 1,107,189 | 1,069,946 | 1,069,946 | 1,583,568 | 1,583,568 | 1,633,082 | 1,633,082 | 2,000,000 | 2,000,000 | 1,934,359 | 1,934,359 | 2,013,424 | 2,013,424 | 2,433,328 | 2,433,328 | 3,030,303 | 3,030,303 | ||||||||||||
Reverse stock split of common stock | 0.75 | ||||||||||||||||||||||||||||||||||||
Number of shares of preferred stock issued upon conversion of note | 2,433,328 | ||||||||||||||||||||||||||||||||||||
Principal amount of the notes converted | 26,444,000 | ||||||||||||||||||||||||||||||||||||
Accrued interest | 323,000 | ||||||||||||||||||||||||||||||||||||
Issue price (in dollars per share) | $ 5.00 | $ 5.75 | $ 3.56 | $ 4.67 | $ 9.76 | $ 11.00 | $ 9.79 | $ 9.79 | $ 11.00 | $ 11.00 | $ 16.50 | $ 16.50 | |||||||||||||||||||||||||
Number of shares of preferred stock issued | 3,030,303 | ||||||||||||||||||||||||||||||||||||
Issuance costs associated with offering | 2,204,000 | ||||||||||||||||||||||||||||||||||||
Composition of share capital | |||||||||||||||||||||||||||||||||||||
Common stock, par value per share (in dollars per share) | $ 0.01 | $ 0.01 | $ 0.01 | ||||||||||||||||||||||||||||||||||
Common stock authorized (in shares) | 30,145,155 | 30,145,155 | 30,145,155 | ||||||||||||||||||||||||||||||||||
Common stock issued (in shares) | 2,609,484 | 2,609,484 | 2,606,484 | ||||||||||||||||||||||||||||||||||
Common stock outstanding (in shares) | 2,609,484 | 2,609,484 | 2,606,484 | ||||||||||||||||||||||||||||||||||
Preferred stock authorized (in shares) | 18,548,253 | 18,548,253 | 18,548,253 | 18,548,253 | 18,548,253 | 400,000 | 400,000 | 1,200,000 | 1,200,000 | 1,200,000 | 1,200,000 | 1,625,000 | 1,625,000 | 1,650,000 | 1,650,000 | 2,000,000 | 2,000,000 | 2,700,000 | 2,700,000 | 2,042,950 | 2,042,950 | 2,700,000 | 2,700,000 | 3,030,303 | 3,030,303 | ||||||||||||
Preferred stock issued (in shares) | 16,912,199 | 16,912,199 | 16,912,199 | 16,912,199 | 16,912,199 | 107,000 | 107,000 | 1,107,189 | 1,107,189 | 1,069,946 | 1,069,946 | 1,583,568 | 1,583,568 | 1,633,082 | 1,633,082 | 2,000,000 | 2,000,000 | 1,934,359 | 1,934,359 | 2,013,424 | 2,013,424 | 2,433,328 | 2,433,328 | 3,030,303 | 3,030,303 | ||||||||||||
Preferred stock outstanding (in shares) | 16,912,199 | 16,912,199 | 0 | 16,912,199 | 107,000 | 107,000 | 1,107,189 | 1,107,189 | 1,069,946 | 1,069,946 | 1,583,568 | 1,583,568 | 1,633,082 | 1,633,082 | 2,000,000 | 2,000,000 | 1,934,359 | 1,934,359 | 2,013,424 | 2,433,328 | 3,030,303 | ||||||||||||||||
Activity of the preferred stock | |||||||||||||||||||||||||||||||||||||
Balance at the beginning of the period (in shares) | 16,912,199 | 0 | 16,912,199 | 107,000 | 107,000 | 1,107,189 | 1,107,189 | 1,069,946 | 1,069,946 | 1,583,568 | 1,583,568 | 1,633,082 | 1,633,082 | 2,000,000 | 2,000,000 | 1,934,359 | 1,934,359 | 2,013,424 | 2,433,328 | 3,030,303 | |||||||||||||||||
Balance at the beginning of the period | 201,315,000 | 535,000 | 535,000 | 12,733,000 | 12,733,000 | 7,618,000 | 7,618,000 | 18,211,000 | 18,211,000 | 18,780,000 | 18,780,000 | 23,000,000 | 23,000,000 | 22,819,000 | 22,819,000 | 22,005,000 | 26,933,000 | 48,681,000 | |||||||||||||||||||
Accretion of redemption premium and issuance costs on Preferred Stock | (2,051,000) | (2,158,000) | 2,051,000 | 767,000 | 200,000 | 1,084,000 | |||||||||||||||||||||||||||||||
Balance at the end of the period (in shares) | 16,912,199 | 16,912,199 | 0 | 16,912,199 | 107,000 | 107,000 | 1,107,189 | 1,107,189 | 1,069,946 | 1,069,946 | 1,583,568 | 1,583,568 | 1,633,082 | 1,633,082 | 2,000,000 | 2,000,000 | 1,934,359 | 1,934,359 | 2,013,424 | 2,433,328 | 3,030,303 | ||||||||||||||||
Balance at the end of the period | 203,366,000 | 535,000 | 535,000 | 12,733,000 | 12,733,000 | 7,618,000 | 7,618,000 | 18,211,000 | 18,211,000 | 18,780,000 | 18,780,000 | 23,000,000 | 23,000,000 | 22,819,000 | 22,819,000 | 22,772,000 | 27,133,000 | 49,765,000 | |||||||||||||||||||
Number of voting rights per share of common stock for each holder of preferred stock | 1 | ||||||||||||||||||||||||||||||||||||
Number of shares of common stock issued for each share of preferred stock | 0.80 | 0.85 | 0.75 | 0.75 | 0.75 | 0.77 | 0.75 | 0.75 | 0.75 | 0.75 | |||||||||||||||||||||||||||
Percentage of holding of outstanding Series A, Series B and Series C Preferred Stock holders from whom the written request required for redemption at specified price | 66.67% | ||||||||||||||||||||||||||||||||||||
Redemption price (in dollars per share) | $ 5.00 | $ 11.50 | $ 7.12 | $ 11.50 | $ 11.50 | $ 11.50 | $ 11.50 | $ 11.50 | $ 11.50 | $ 18.00 | |||||||||||||||||||||||||||
Number of days after receipt of the written request for redemption considered for determining redemption date | 60 days | ||||||||||||||||||||||||||||||||||||
Number of series of preferred stock contemporaneously subject to redemption considered for following liquidation order of priority | 1 | ||||||||||||||||||||||||||||||||||||
Aggregate redemption value of preferred stock | 103,122,000 | 82,529,000 | 23,154,000 | ||||||||||||||||||||||||||||||||||
Number of warrants issued (in shares) | 6,128 | 6,128 | |||||||||||||||||||||||||||||||||||
Ratio of the number of warrants issued for each share of preferred stock purchased | 0.50 | 0.50 | |||||||||||||||||||||||||||||||||||
Weighted average assumptions | |||||||||||||||||||||||||||||||||||||
Exercise price (in dollars per share) | $ 9.79 | $ 9.79 | |||||||||||||||||||||||||||||||||||
Share price (in dollars per share) | $ 9.79 | $ 9.79 | |||||||||||||||||||||||||||||||||||
Expected term | 3 years | ||||||||||||||||||||||||||||||||||||
Risk-free rate (as a percent) | 1.52% | ||||||||||||||||||||||||||||||||||||
Volatility (as a percent) | 85.46% | ||||||||||||||||||||||||||||||||||||
Change in fair value of warrant liability | $ (2,000) | $ 999,000 | $ 12,000 | $ 390,000 | $ (2,000) | $ 12,000 |
X | ||||||||||
- Definition
The number of warrants issued during the period. No definition available.
|
X | ||||||||||
- Definition
Represents the number of votes per share of common stock, which holders of outstanding shares of preferred stock are entitled to receive. No definition available.
|
X | ||||||||||
- Details
|
X | ||||||||||
- Definition
Represents the number of days after receipt of the written request for redemption considered for determining redemption date. No definition available.
|
X | ||||||||||
- Definition
Represents the number of series of preferred stock contemporaneously subject to redemption considered for following liquidation order of priority. No definition available.
|
X | ||||||||||
- Definition
Represents the percentage of holding of outstanding Series A, Series B and Series C preferred stock holders from whom the written request required for redemption at specified price. No definition available.
|
X | ||||||||||
- Definition
The ratio of the number of warrants issued for each share of preferred stock purchased. No definition available.
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
X | ||||||||||
- Details
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
X | ||||||||||
- Details
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
X | ||||||||||
- Details
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
X | ||||||||||
- Definition
Amount of increase in additional paid in capital (APIC) resulting from modification of stock option awards. No definition available.
|
X | ||||||||||
- Definition
Represents the increase (decrease) in the intrinsic value of awards upon re-measurement. No definition available.
|
X | ||||||||||
- Definition
Represents the minimum period for which common stock is to be held by option holder prior to selling such common stock to the significant holder. No definition available.
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|
X | ||||||||||
- Definition
Represents the percentage increase in the number of shares reserved for issuance under the plan equal to fully diluted shares calculated annually on a specified date. No definition available.
|
X | ||||||||||
- Definition
Represents the amount of reclassification of award liabilities to the stockholders' deficit during the period. No definition available.
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
X | ||||||||||
- Details
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
X | ||||||||||
- Details
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
X | ||||||||||
- Details
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
X | ||||||||||
- Details
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
X | ||||||||||
- Details
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
X | ||||||||||
- Details
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
Stock-Based Compensation (Details 2) (USD $)
|
3 Months Ended | 6 Months Ended | ||
---|---|---|---|---|
Jun. 30, 2013
|
Jun. 30, 2012
|
Jun. 30, 2013
|
Jun. 30, 2012
|
|
Stock-based compensation | ||||
Total stock-based compensation | $ 379,000 | $ 103,000 | $ 2,843,000 | $ 2,540,000 |
Unrecognized compensation expense | 2,351,000 | 2,351,000 | ||
Weighted-average period for recognizing unrecognized compensation expense | 2 years 29 days | |||
General and administrative
|
||||
Stock-based compensation | ||||
Total stock-based compensation | 220,000 | 54,000 | 1,526,000 | 1,321,000 |
Research and development
|
||||
Stock-based compensation | ||||
Total stock-based compensation | $ 159,000 | $ 49,000 | $ 1,317,000 | $ 1,219,000 |
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
X | ||||||||||
- Details
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
X | ||||||||||
- Details
|
X | ||||||||||
- Definition
Represents the exercise price for purpose of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards. No definition available.
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
License and Collaboration Agreements (Details) (USD $)
|
3 Months Ended | 6 Months Ended | 1 Months Ended | 3 Months Ended | 6 Months Ended | 1 Months Ended | 3 Months Ended | 6 Months Ended | 3 Months Ended | 6 Months Ended | 1 Months Ended | 1 Months Ended | |||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2013
|
Jun. 30, 2012
|
Jun. 30, 2013
|
Jun. 30, 2012
|
Sep. 30, 2012
Baxter
Maximum
item
|
Sep. 30, 2012
Collaboration arrangement
Baxter
|
Jun. 30, 2013
Collaboration arrangement
Baxter
|
Jun. 30, 2013
Collaboration arrangement
Baxter
|
Sep. 30, 2012
Collaboration arrangement
Rigosertib
Baxter
item
|
Sep. 30, 2012
Collaboration arrangement
Rigosertib
Baxter
Minimum
|
Sep. 30, 2012
Collaboration arrangement
Rigosertib
Baxter
Maximum
|
Sep. 30, 2012
Collaboration arrangement
Rigosertib
Baxter
Rigosertib intravenous ("IV") in higher risk myelodysplastic syndrome ("MDS") patients
|
Sep. 30, 2012
Collaboration arrangement
Rigosertib
Baxter
Rigosertib intravenous ("IV") in higher risk myelodysplastic syndrome ("MDS") patients
Minimum
|
Sep. 30, 2012
Collaboration arrangement
Rigosertib
Baxter
Rigosertib IV in pancreatic cancer patients
|
Sep. 30, 2012
Collaboration arrangement
Rigosertib
Baxter
Rigosertib IV in pancreatic cancer patients
Minimum
|
Sep. 30, 2012
Collaboration arrangement
Rigosertib
Baxter
Rigosertib oral in lower risk MDS patients
|
Sep. 30, 2012
Collaboration arrangement
Rigosertib
Baxter
Rigosertib oral in lower risk MDS patients
Minimum
|
Jul. 31, 2011
Collaboration arrangement
Rigosertib
SymBio
|
Jun. 30, 2013
Collaboration arrangement
Rigosertib
SymBio
|
Jun. 30, 2012
Collaboration arrangement
Rigosertib
SymBio
|
Jun. 30, 2013
Collaboration arrangement
Rigosertib
SymBio
|
Jun. 30, 2012
Collaboration arrangement
Rigosertib
SymBio
|
Jun. 30, 2013
Collaboration arrangement
Rigosertib
SymBio
Supply agreement
|
Jun. 30, 2012
Collaboration arrangement
Rigosertib
SymBio
Supply agreement
|
Jun. 30, 2013
Collaboration arrangement
Rigosertib
SymBio
Supply agreement
|
Jun. 30, 2012
Collaboration arrangement
Rigosertib
SymBio
Supply agreement
|
Jul. 31, 2011
Collaboration arrangement
Rigosertib
SymBio
Supply agreement
|
Jul. 31, 2011
Collaboration arrangement
Rigosertib
SymBio
United States and Japan
|
Jul. 31, 2011
Collaboration arrangement
Rigosertib
SymBio
Maximum
|
Jul. 31, 2011
Collaboration arrangement
Rigosertib
SymBio
Rigosertib intravenous ("IV") in higher risk myelodysplastic syndrome ("MDS") patients
United States
|
Jul. 31, 2011
Collaboration arrangement
Rigosertib
SymBio
Rigosertib intravenous ("IV") in higher risk myelodysplastic syndrome ("MDS") patients
Japan
|
Jul. 31, 2011
Collaboration arrangement
Rigosertib
SymBio
Rigosertib oral in lower risk MDS patients
United States
|
Jul. 31, 2011
Collaboration arrangement
Rigosertib
SymBio
Rigosertib oral in lower risk MDS patients
Japan
|
Jul. 31, 2011
Collaboration arrangement
Rigosertib
SymBio
Rigosertib IV in combination with gemcitabine for pancreatic cancer patients
United States
|
Jul. 31, 2011
Collaboration arrangement
Rigosertib
SymBio
Rigosertib IV in combination with gemcitabine for pancreatic cancer patients
Japan
|
|
License and collaboration agreements | |||||||||||||||||||||||||||||||||||
Number of initial rigosertib indications | 3 | ||||||||||||||||||||||||||||||||||
Upfront payment | $ 50,000,000 | $ 7,500,000 | |||||||||||||||||||||||||||||||||
Aggregate milestone payments | 512,500,000 | 33,000,000 | |||||||||||||||||||||||||||||||||
Potential pre-commercial milestone payments for successful completion of a Phase 3 clinical trial for indication | 50,000,000 | ||||||||||||||||||||||||||||||||||
Potential pre-commercial milestone payments for joint decisions to proceed with the development of rigosertib for certain indications | 25,000,000 | 25,000,000 | |||||||||||||||||||||||||||||||||
Number of joint decisions to proceed with the development of rigosertib for specified indications | 2 | ||||||||||||||||||||||||||||||||||
Potential pre-commercial milestone payments for drug approval application filed for specified indications | 25,000,000 | 25,000,000 | 25,000,000 | ||||||||||||||||||||||||||||||||
Potential milestone payments for regulatory approvals of specified indications | 337,500,000 | 100,000,000 | 100,000,000 | 100,000,000 | |||||||||||||||||||||||||||||||
Additional potential pre-commercial milestone payments related to the timing of regulatory approval of indication | 20,000,000 | ||||||||||||||||||||||||||||||||||
Aggregate potential milestone payments based on annual net sales of rigosertib | 250,000,000 | 30,000,000 | |||||||||||||||||||||||||||||||||
Percentage of royalty payments based on net sales of rigosertib | 10.00% | 20.00% | 20.00% | ||||||||||||||||||||||||||||||||
Number of employees | 50,000 | ||||||||||||||||||||||||||||||||||
Discount rate (as a percent) | 16.00% | ||||||||||||||||||||||||||||||||||
BESP of the license | 120,000,000 | ||||||||||||||||||||||||||||||||||
BESP of the research and development services | 20,600,000 | ||||||||||||||||||||||||||||||||||
Up-front payment allocated to license | 42,400,000 | ||||||||||||||||||||||||||||||||||
Up-front payment allocated to research and development services | 7,600,000 | ||||||||||||||||||||||||||||||||||
Allocated up-front payment of license recognized upon execution of agreement | 42,400,000 | ||||||||||||||||||||||||||||||||||
Research and development revenue | 990,000 | 1,456,000 | |||||||||||||||||||||||||||||||||
Consideration received for the Preferred Stock | 50,000,000 | ||||||||||||||||||||||||||||||||||
Potential development milestones payments due after enrollment of the first patient in event of decision made to start phase 3 clinical trial of indication | 3,000,000 | ||||||||||||||||||||||||||||||||||
Regulatory milestones payments due upon receipt of marketing approval for indication | 5,000,000 | 3,000,000 | 5,000,000 | 5,000,000 | 5,000,000 | 3,000,000 | |||||||||||||||||||||||||||||
Aggregate milestone payments due upon receipt of marketing approval for an additional indication | 4,000,000 | ||||||||||||||||||||||||||||||||||
Binding commitments | 0 | ||||||||||||||||||||||||||||||||||
Recognized revenues | $ 591,000 | $ 220,000 | $ 1,707,000 | $ 418,000 | $ 113,000 | $ 113,000 | $ 227,000 | $ 227,000 | $ 0 | $ 10,000 | $ 24,000 | $ 10,000 |
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
X | ||||||||||
- Definition
The aggregate amount of payments that could be received for the achievement of certain specified development and regulatory milestones under the arrangement. No definition available.
|
X | ||||||||||
- Definition
The aggregate amount of payments that could be received based on achievement of annual net sales under the arrangement. No definition available.
|
X | ||||||||||
- Definition
Represents the best estimated amount of selling price of license under the arrangement. No definition available.
|
X | ||||||||||
- Definition
Represents the number of initial indications for which research and development is performed through different phases under the arrangement. No definition available.
|
X | ||||||||||
- Definition
Represents the number of joint decisions to proceed with development for indications specified under the arrangement. No definition available.
|
X | ||||||||||
- Definition
Represents the percentage of royalty payments based on net sales under the arrangement. No definition available.
|
X | ||||||||||
- Definition
Represents the amount of potential development milestones due after the enrollment of the first patient in the event of decision made after the entity's interim analysis to start phase 3 clinical trial for indication under the arrangement. No definition available.
|
X | ||||||||||
- Definition
Represents the aggregate amount of payments that could be received upon receipt of marketing approval for additional indications under the arrangement. No definition available.
|
X | ||||||||||
- Definition
Represents the amount of regulatory milestones payments due upon receipt of marketing approval for indications under the arrangement. No definition available.
|
X | ||||||||||
- Definition
The additional amount of pre-commercial payments that could be received for timing of regulatory approval of indication specified under the arrangement. No definition available.
|
X | ||||||||||
- Definition
The amount of pre-commercial payments that could be received for drug approval application filed for specified indications under the arrangement. No definition available.
|
X | ||||||||||
- Definition
The amount of pre-commercial payments that could be received for the joint decisions to proceed with development for indications specified under the arrangement. No definition available.
|
X | ||||||||||
- Definition
The amount of pre-commercial payments that could be received for regulatory approval of specified indications under the arrangement. No definition available.
|
X | ||||||||||
- Definition
The amount of pre-commercial payments that could be received for successful completion of a Phase 3 clinical trial for indications under the arrangement. No definition available.
|
X | ||||||||||
- Definition
Represents the best estimated amount of selling price of research and development services arrangement. No definition available.
|
X | ||||||||||
- Definition
Represents the amount of upfront payment paid to the entity under the arrangement. No definition available.
|
X | ||||||||||
- Definition
Represents the amount of upfront payment allocated to license based on best estimate of selling price under the arrangement. No definition available.
|
X | ||||||||||
- Definition
Represents the allocated amount to license of upfront payment recognized upon the execution of agreement under the arrangement. No definition available.
|
X | ||||||||||
- Definition
Represents the amount of upfront payment allocated to research and development services based on best estimate of selling price under the arrangement. No definition available.
|
X | ||||||||||
- Definition
Aggregate revenue earned by the entity during the period under its collaboration agreements for reimbursement of research and development services, reimbursement of development costs, amortization of up-front payments and certain milestone payments. No definition available.
|
X | ||||||||||
- Details
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
Joint Venture (Details)
|
Dec. 31, 2012
item
|
---|---|
Joint Venture | |
Number of new programs to be collaborated and developed | 2 |
X | ||||||||||
- Definition
Represents the number of new programs to be collaborated and developed by the joint venture. No definition available.
|
X | ||||||||||
- Details
|
Related-Party Transactions (Details) (USD $)
|
3 Months Ended | 6 Months Ended | ||
---|---|---|---|---|
Jun. 30, 2013
|
Jun. 30, 2012
|
Jun. 30, 2013
|
Jun. 30, 2012
|
|
Mount Sinai
|
||||
Related-party transactions | ||||
Payments to related party | $ 198,000 | $ 285,000 | $ 225,000 | $ 469,000 |
Amounts due to related party | 295,000 | 0 | 295,000 | 0 |
Supplier business owned by board members
|
||||
Related-party transactions | ||||
Payments to related party | 0 | 0 | 107,000 | 52,500 |
Amounts due to related party | 0 | 9,000 | 0 | 9,000 |
Corporations owned by former board members
|
||||
Related-party transactions | ||||
Payments to related party | 212,000 | 173,000 | 240,000 | 452,000 |
Amounts due to related party | $ 31,000 | $ 0 | $ 31,000 | $ 0 |
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
X | ||||||||||
- Details
|
Subsequent Event (Details) (USD $)
|
0 Months Ended | 0 Months Ended | |||||||
---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2013
|
Dec. 31, 2012
|
Jun. 30, 2012
|
Dec. 31, 2011
|
Jul. 25, 2013
Subsequent event
|
Jul. 17, 2013
Subsequent event
|
Jul. 31, 2013
Subsequent event
|
Jul. 30, 2013
Subsequent event
|
Jul. 30, 2013
Subsequent event
IPO
|
|
Subsequent events | |||||||||
Preferred stock outstanding (in shares) | 16,912,199 | 16,912,199 | 0 | ||||||
Net proceeds received from the sale, net of underwriting discounts and commissions and other estimated offering expenses | $ 79,600,000 | ||||||||
Reverse stock split of common stock | 0.75 | ||||||||
Designated public offering amended threshold gross proceeds, minimum | $ 25,000,000 | ||||||||
Number of shares of common stock reserved for issuance | 3,081,644 | 3,081,644 | 2,285,803 | 2,285,803 | 6,107,831 | ||||
Number of shares of common stock available for future issuance | 3,315,662 | ||||||||
Number of shares of stock options issued in conjunction with the IPO | 485,500 |
X | ||||||||||
- Definition
Represents the minimum threshold amount of gross proceeds under the entity's amended certificate of incorporation in the definition of a designated public offering. No definition available.
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|
X | ||||||||||
- Details
|
X | ||||||||||
- Definition
No authoritative reference available. No definition available.
|